Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by crow27on Feb 28, 2021 2:40pm
357 Views
Post# 32681998

Insiders/Shorts.

Insiders/Shorts.Just remember that management can only buy shares at certain times during the year. Many times it is blacked out and they can not buy. Buying as they did tells me they want in before more news breaks. They know exactly what is coming down the pipe and don't lose site of that. Paying in the $6.00 range will look like a steal soon enough. I have seen this with many stocks, insiders buy and the stock drifts lower and everyone is laughing at them, and all of a sudden the stock starts to rise and then a juicy news release comes out and then they are all in the money. If you look at all the gas in their tank and what can be released on any day, you realize this stock will be going higher.
And to be worried because there are 100,000 shares being shorted is a total joke. This could be covered in a  5 min of trading once it starts rising. Nothing at all to be concerned with.
Accumulate, sit tight and wait for the NR's that are just around the corner.
This can get over $10.00 in no time at all. The writing is on the wall for much better days. Announce another bigger partner deal and it could jump to $10.00 in one day. Don't be sitting outside looking in is all I can say. This is a bio stock and good news just vaults them much, much higher in a heartbeat. Wait for the news????
<< Previous
Bullboard Posts
Next >>